IGC

← Markets

IGCIGC Pharma, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Mon, Aug 17
7:30 AMYahooIGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
Tue, Aug 11
7:30 AMYahooIGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
Wed, Jul 29
7:30 AMYahooIGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
Thu, Jul 9
8:00 AMYahooIGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
Tue, Jul 7
8:00 AMYahooIGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
Tue, Jun 23
7:30 AMYahooIGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
Thu, Jun 11
7:30 AMYahooIGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
Tue, Jun 9
7:30 AMYahooAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
Tue, Jun 2
7:30 AMYahooIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
Tue, May 19
4:30 PMYahooIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
Fri, May 15
7:00 AMYahooIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference